Literature DB >> 579342

Pharmacokinetics of tolamolol in the treatment of hypertension.

P A Routledge, D M Davies, M D Rawlins.   

Abstract

Tolamolol was administered in a "double-blind" study to fifteen hypertensive patients by dose-titration against arterial blood pressure. Mean steady-state plasma tolamolol concentrations (Css) were determined for each patient from the area under the plasma concentration--time curve during a dosage interval whilst patients were receiving optimal tolamolol doses. No significant correlation was observed between daily tolamolol dose and Css; the relationship between fall in lying mean arterial pressure and Css also failed to reach conventional levels of statistical significance, but Css was observed to be correlated with the fall in standing pressure. The results suggest that plasma concentrations in excess of 200 ng/ml may be required to achieve an effective hypothensive response with the drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 579342     DOI: 10.1007/bf00609855

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man.

Authors:  C Bahr; G Alván; M Lind; B Mellström; V Sjöqvist
Journal:  Acta Pharm Suec       Date:  1974-12

2.  ZERO-MUDDLER FOR UNPREJUDICED SPHYGMOMANOMETRY.

Authors:  J S GARROW
Journal:  Lancet       Date:  1963-12-07       Impact factor: 79.321

3.  Thin layer chromatography-fluorimetic estimation of tolamolol in human plasma.

Authors:  D A Stopher
Journal:  J Pharm Pharmacol       Date:  1975-02       Impact factor: 3.765

Review 4.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

5.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

6.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

7.  Pharmacokinetic and pharmacological studies with tolamolol in man.

Authors:  J K Faulkner; D A Stopher; R Walden
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

8.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

9.  Dose-titrated, double-blind, cross-over comparison of a selective beta-blocker and methyldopa in the treatment of hypertension.

Authors:  P A Routledge; L V Zrinzo; J G Rao; R J Walden; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

10.  Assessment of selective beta-adrenoceptor blockade in man.

Authors:  R H Briant; C T Dollery; T Fenyvesi; C F George
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

View more
  1 in total

1.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.